Scientific Timeline
The Evolution of Psychedelic Research
Over the past century, scientific interest in psychedelic compounds has undergone dramatic shifts — from pioneering pharmacological studies in the early 1900s, through decades of prohibition that nearly halted all research, to an unprecedented renaissance that has produced more peer-reviewed publications since 2010 than in all prior decades combined. This page traces that journey through data, milestones, and institutional developments.
For the broader cultural and social history of psychedelics, visit Psyzone History
Publication Trends Over Time
Early Pharmacology
The scientific study of psychedelic compounds began with the isolation of mescaline from peyote in 1897 by Arthur Heffter, followed by its synthesis in 1919 by Ernst Späth. Albert Hofmann's accidental discovery of LSD's psychoactive effects in 1943 at Sandoz Laboratories opened a new era of psychiatric research. By the 1950s, LSD and mescaline were being studied in over 40 research institutions worldwide. Approximately 1,000 clinical papers were published between 1950 and 1965, exploring applications ranging from alcoholism treatment to psychotherapy enhancement. The isolation of psilocybin and psilocin from Psilocybe mushrooms by Hofmann in 1958, following R. Gordon Wasson's ethnomycological fieldwork, further expanded the research landscape.
Mescaline Isolated
Arthur Heffter isolates mescaline from peyote cactus, establishing the first identified psychedelic compound.
LSD Synthesized
Albert Hofmann synthesizes lysergic acid diethylamide (LSD-25) at Sandoz Laboratories in Basel, Switzerland.
LSD Psychoactive Effects Discovered
Hofmann accidentally absorbs LSD and discovers its powerful psychoactive properties, leading to systematic self-experimentation.
First Published LSD Study
Werner Stoll publishes the first scientific paper on LSD's psychological effects in the Swiss Archives of Neurology.
Psilocybin Isolated
Albert Hofmann isolates psilocybin and psilocin from Psilocybe mexicana mushrooms, enabling standardized clinical research.
Prohibition & Decline
The intersection of psychedelic research with 1960s counterculture politics led to a rapid regulatory backlash. The US banned LSD in 1966, and the Controlled Substances Act of 1970 placed most psychedelics in Schedule I — the most restrictive category, defined as having 'no currently accepted medical use.' Similar restrictions spread internationally. The effect on research was devastating: funding disappeared, institutional review boards refused new protocols, and career risks deterred investigators. Annual publications dropped from hundreds to single digits. It is worth noting that this classification was primarily a political response, not one driven by scientific consensus on therapeutic potential — a point that prominent researchers of the era, including Stanislav Grof, documented extensively.
LSD Banned in the United States
States begin outlawing LSD. Sandoz withdraws the drug from the market and halts distribution to researchers.
Controlled Substances Act
The US Controlled Substances Act classifies LSD, psilocybin, mescaline, and DMT as Schedule I, effectively prohibiting clinical research.
UN Convention on Psychotropic Substances
International treaty extends scheduling of psychedelics globally, harmonizing prohibition across signatory nations.
Quiet Persistence
Despite the regulatory environment, a small number of researchers maintained interest in psychedelic science. Rick Strassman at the University of New Mexico obtained FDA approval in 1990 for the first new human study with a psychedelic in over 20 years — a landmark DMT trial published in 1994. The founding of the Multidisciplinary Association for Psychedelic Studies (MAPS) by Rick Doblin in 1986 created an organizational infrastructure for sponsoring clinical trials. Franz Vollenweider's psilocybin neuroimaging studies in Zurich provided early brain-imaging data. These efforts, though modest in scale, established the regulatory precedents and institutional relationships that would prove essential for the renaissance that followed.
MAPS Founded
Rick Doblin founds the Multidisciplinary Association for Psychedelic Studies, creating the first organization dedicated to sponsoring psychedelic clinical trials.
Strassman's DMT Study Published
Rick Strassman publishes results from the first FDA-approved psychedelic study in over 20 years, studying DMT in human volunteers.
Vollenweider Psilocybin Neuroimaging
Franz Vollenweider publishes pioneering neuroimaging studies of psilocybin's effects on brain activity at the University of Zurich.
Scientific Renaissance
The publication of Roland Griffiths' landmark 2006 psilocybin study at Johns Hopkins marked a turning point. Using rigorous double-blind methodology, the study demonstrated that psilocybin could occasion mystical-type experiences with lasting positive effects — and it was published in Psychopharmacology, a mainstream journal. This opened the floodgates. The number of annual publications began growing exponentially. Key developments included: Robin Carhart-Harris's brain imaging studies at Imperial College London revealing psilocybin's mechanism via the default mode network (2012), MAPS-sponsored MDMA trials for PTSD receiving FDA Breakthrough Therapy designation (2017), and the establishment of dedicated psychedelic research centers at Johns Hopkins (2019) and Imperial College. By 2020, annual psychedelic publications exceeded those of the entire 1950–2000 period combined.
Griffiths Psilocybin Study
Roland Griffiths publishes the landmark Johns Hopkins psilocybin study in Psychopharmacology, catalyzing renewed mainstream scientific interest.
Default Mode Network Discovery
Robin Carhart-Harris at Imperial College publishes findings showing psilocybin reduces activity in the brain's default mode network, providing a neurobiological framework.
MDMA Receives FDA Breakthrough Therapy
The FDA grants Breakthrough Therapy designation to MDMA-assisted therapy for PTSD, sponsored by MAPS, accelerating the path to potential approval.
Johns Hopkins Center Established
Johns Hopkins University opens the Center for Psychedelic and Consciousness Research with $17M in funding — the first such center at a major US institution.
Esketamine Approved by FDA
The FDA approves esketamine (Spravato) nasal spray for treatment-resistant depression, the first psychedelic-adjacent compound to receive full regulatory approval.
Modern Expansion
The current period is characterized by unprecedented institutional growth, regulatory milestones, and research volume. MAPS completed Phase 3 trials for MDMA-assisted therapy for PTSD. Oregon (2020) and Colorado (2022) passed ballot measures creating legal frameworks for psilocybin therapy. Australia became the first country to reschedule psilocybin and MDMA for therapeutic use (2023). New research centers have opened at institutions including UC Berkeley, UC San Francisco, Yale, and NYU. Industry investment has surged, with multiple biotech companies pursuing psychedelic drug development. Annual publication counts now exceed 1,000 papers per year. However, the field faces challenges: the FDA's 2024 rejection of MAPS/Lykos Therapeutics' MDMA NDA highlighted ongoing regulatory complexity, and questions about scalability, training standards, and equitable access remain active areas of discussion.
Oregon Measure 109
Oregon voters approve Measure 109, creating the first US legal framework for psilocybin-assisted therapy services.
Colorado Natural Medicine Health Act
Colorado passes Proposition 122, decriminalizing psilocybin and creating a regulated access program for psychedelic therapy.
Australia Reschedules Psilocybin and MDMA
Australia's TGA reschedules psilocybin and MDMA for therapeutic use under psychiatrist supervision — the first national-level rescheduling.
FDA Rejects MDMA NDA
The FDA issues a Complete Response Letter for Lykos Therapeutics' MDMA-assisted therapy NDA, requesting additional trials and raising methodological questions.
Leading Research Institutions
These institutions have been at the forefront of psychedelic science, producing foundational research that shapes the field today.
MAPS / Lykos Therapeutics
Founded in 1986, MAPS has been the primary sponsor of MDMA-assisted therapy clinical trials, advancing psychedelic medicine through regulatory pathways and public education.
Johns Hopkins Center for Psychedelic & Consciousness Research
Established in 2019 with $17M in private funding, the center has produced landmark studies on psilocybin for depression, addiction, and existential distress in cancer patients.
Imperial College Centre for Psychedelic Research
Led by Robin Carhart-Harris, this center pioneered neuroimaging studies of psychedelics and conducted the first modern clinical trial comparing psilocybin to escitalopram for depression.
Beckley Foundation
Founded by Amanda Feilding, the Beckley Foundation has supported psychedelic research for over two decades, funding key studies on LSD, psilocybin, and cannabis through academic collaborations.
Usona Institute
A medical research organization conducting FDA-regulated clinical trials of psilocybin for major depressive disorder, with a focus on developing psilocybin as an FDA-approved medicine.
An Evolving Landscape
The trajectory of psychedelic research over the past century reveals a field profoundly shaped by political, cultural, and regulatory forces — often more so than by scientific evidence itself. The data shows a clear pattern: robust early investigation, near-total suppression during prohibition, and an exponential resurgence driven by rigorous modern methodology. Today's research volume surpasses all historical periods combined, supported by dedicated institutions, substantial funding, and evolving regulatory frameworks. Whether this momentum translates into broadly accessible, evidence-based therapies remains an open question — one that will be answered by the quality and rigor of ongoing and future clinical investigations. This timeline presents the documented record; the conclusions belong to the evidence.